Overview
- Prelude Growth Partners led the $27 million investment with participation from Unilever Ventures, Willow Growth Partners and Selva Ventures.
- The deal replaces early angel investors as Perelel prepares for its next phase of growth.
- Perelel reports profitability and says revenue has more than doubled each year since launch in 2020.
- The company plans to expand products across the female hormonal lifecycle and increase formal clinical validation of its formulas.
- Perelel sells direct-to-consumer, on Amazon and at Erewhon, and has run clinicals on products including Women’s Daily Vitamin Trio and Hormone Balance Support.